What this means
This is a plan for a small study on whether a weight-loss drug changes muscle and blood vessel health. It has not started giving results yet, so it cannot tell us what the effects are.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 50 and over
- Where
- 1 site, including Texas
The science
- Registered title
- Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
- Trial ID
- NCT06811324 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
- What is tested
- Tirzepatide
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Ages
- 50 Years to no maximum
- Dates
- First posted Feb 6, 2025 · updated Apr 15, 2026
Registry summary
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.
Sites (1)
- University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States